Used primarily as an antibacterial agent, particularly effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It is being developed for the treatment of serious skin and soft tissue infections, as well as bloodstream infections. Its mechanism allows for once-daily intravenous administration, offering potential for both hospital and outpatient use. Due to its narrow spectrum and targeted activity, it may help reduce collateral damage to normal flora, potentially lowering the risk of secondary infections like Clostridioides difficile. Currently under clinical investigation, it represents a promising option in the fight against multidrug-resistant pathogens.